USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) insider Joshua Foukas sold 5,732 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total transaction of $186,519.28. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
USANA Health Sciences Stock Performance
USNA stock opened at $30.38 on Friday. The company has a fifty day moving average price of $32.79 and a 200-day moving average price of $36.05. The company has a market capitalization of $579.12 million, a P/E ratio of 10.74, a PEG ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a 52-week low of $27.71 and a 52-week high of $50.32.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The firm had revenue of $213.61 million during the quarter, compared to the consensus estimate of $208.82 million. As a group, sell-side analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Institutional Investors Weigh In On USANA Health Sciences
A number of large investors have recently bought and sold shares of USNA. R Squared Ltd acquired a new position in shares of USANA Health Sciences during the fourth quarter valued at about $28,000. Safe Harbor Fiduciary LLC bought a new stake in USANA Health Sciences in the third quarter worth about $30,000. KBC Group NV raised its position in USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company's stock worth $40,000 after acquiring an additional 519 shares during the period. KLP Kapitalforvaltning AS bought a new stake in USANA Health Sciences in the fourth quarter worth about $83,000. Finally, Quantbot Technologies LP bought a new stake in USANA Health Sciences in the fourth quarter worth about $132,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research firms have weighed in on USNA. DA Davidson lowered their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th. Finally, StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th.
Check Out Our Latest Analysis on USNA
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
